Skip to main content
Journal of Bone and Mineral Research logoLink to Journal of Bone and Mineral Research
editorial
. 2025 Mar 5;40(5):569–571. doi: 10.1093/jbmr/zjaf036

Vitamin D and disease prevention in 2024: commentary on recent Endocrine Society recommendations

Catherine M Gordon 1,✉, Meryl S LeBoff 2
PMCID: PMC12103718  PMID: 40044125

The role of vitamin D in calcium absorption, bone, and mineral metabolism is well-established, but what is deemed to be the most appropriate screening, supplementation, and treatment practices has been a topic of controversy. Vitamin D is of high interest to clinicians across many specialties, as well as the age spectrum, as causal links have been suggested between serum 25(OH)D concentrations and a number of diseases, including musculoskeletal, cardiovascular, oncologic, inflammatory, and autoimmune diagnoses, and common infectious diseases.1,2 These suggested associations have led to extensive testing, and in many cases likely prematurely, and before causality has been established between 25(OH)D levels and the condition of concern. In children, adolescents, and adults, what 25(OH)D level represents the “optimal” one for a number of health outcomes also remains unclear. Of note, while previous vitamin D guidelines have been published by a number of scientific and professional societies, including in 2011 by the Endocrine Society2–4 the audience to whom the guidelines are addressing has varied and been a source of confusion.

Demay et al. recently published an Endocrine Society Clinical Practice Guideline (CPG) in 2024, which aimed to provide guidance for the use of vitamin D [cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2)] to lower disease risk.5 These recommendations apply to generally children, adolescents, and adults without established indications for either 25(OH)D screening or vitamin D treatment above the Dietary Reference Intakes (DRI). A multidisciplinary panel of clinical experts was assembled in addition to experts in guideline methodology and systematic literature reviews. They identified 14 questions related to vitamin D use and 25(OH)D testing to lower the risk of disease, and considered only data from randomized controlled trials. Of note, some of the trials considered included a true placebo group, while others allowed participants to continue to receive vitamin D supplementation (600-800 IU daily), the latter design with the potential to diminish a treatment effect. They considered the effects of supplemental vitamin D on individuals across the lifespan and also in two select conditions—pregnant individuals and those with prediabetes. The authors defined “empiric supplementation” as intake of vitamin D that would exceed the Dietary Reference Intake and was initiated in the absence of 25(OH)D testing. The final guidelines aimed to provide recommendations across the age spectrum, from age 1 to 70 yr and elders, >75 yr old. As the authors note, their focus differed from that of the previous 2011 Endocrine Society guidelines on this topic that centered on individuals who were noted to be at risk for either vitamin D deficiency or carry a medical diagnosis for which vitamin D deficiency might lead to worsening of a condition (Table 1). Unfortunately, there has been discussion that these new guidelines “refute” many of the 2011 Endocrine Society recommendations2; it is important to note that the target population was different this time.

Table 1.

2024 vs 2011 Endocrine Society Clinical Guideline on Vitamin D.

  2011 Recommendations (at-risk for deficiency) 2024 Recommendations (healthy population)
Age (yr)
 0-1 400-1000 IU Not included
 1-18 600-1000 IU Empiric vitamin D supplementation
Daily dosage 300-2000 IU
 19-50 600-2000 IU Advise against empiric supplementation exceeding DRI of 600 IU daily
Against routine 25(OH)D testing
 50-69 1500-2000 IU Advice against empiric supplementation exceeding DRI of 600 IU daily
Against routine 25(OH)D testing
 70-74 1500-2000 IU Advise against routine supplementation exceeding 800 IU daily
Against 25(OH)D testing
 75+ 800-2000 IU Empiric supplementation to lower risk of mortality
Daily dosage 400-3333 IU
Advise against testing for 25(OH)D
Pregnant/lactating 600 IU Empiric supplementation to lower risk of adverse maternal and neonatal outcomes
Dosage range 600-5000 IU daily
Advise against routine 25(OH)D testing
Adults with high-risk prediabetes Not included Empiric supplementation to reduce progression to diabetes
Daily dosage 842-7543 IU
Lifestyle modification
Adults with dark skin complexion Not included Advise against routine screening—25(OH)D
Adults with obesity Not included Advise against routine screening—25(OH)D

Abbreviation: DRI, dietary reference intake.

Among the pediatric age groups, vitamin D is known to be important for growth and both bone development and bone mineral accrual.1,4,6 Therefore, the expert panel decided to recommend empiric supplementation to children and adolescents, aged 1-18 yr, bypassing vitamin D screening in an otherwise healthy child or teenager. An aim of empiric supplementation is to prevent the well-documented nutritional rickets and a potential benefit of lowering the risk of respiratory infections and treating infections, including tuberculosis.7 Infants were excluded from consideration as a number of guidelines exist establishing the benefits of empiric vitamin D supplementation during the first year of life to prevent nutritional rickets.3,4,6 Children <1 yr of age represent a vulnerable age group, and especially those who are breastfed and not receiving vitamin D supplementation. The panel noted that the incidence of nutritional rickets to be rising in high-income countries. While factors within racial and minority groups are mentioned, including high cutaneous melanin content that would necessitate longer sun exposure to achieve adequate cutaneous vitamin D synthesis, the impact of sunscreen that blocks cutaneous synthesis is not discussed. Sunscreen use is strongly endorsed for the pediatric age group by pediatricians and dermatologists for both children and adults.8,9 This ongoing controversy was not mentioned in the report and would be another reason to endorse empiric oral supplementation in some groups.

In contrast, in adults, aged 19-74 yr, the panel recommended against routine vitamin D supplementation [that exceeds the dietary reference intakes (DRI) for age] established by the Institute of Medicine (ie, National Academy of Medicine), now also called the Dietary Reference Values (DRVs) in Europe. Adults are recommended to consume the DRI through foods and/or a multivitamin or vitamin D supplement amounting to 600 IU (15 μg) for those 50-70 yr, and 800 IU (20 μg) for those older than 70. Lower dose daily vs nondaily higher dose vitamin D supplementation or treatment was also recommended. The panel also recognized that for individuals aged 75 yr and older in the generally healthy population, empiric supplementation is recommended to lower the risk of mortality, but routine testing is not recommended. As summarized in the recent US Preventative Services Task Force (USPSTF) review, additional supplementation with vitamin D with or without calcium is not currently recommended for community-dwelling, postmenopausal women and men ≥60 yr of age for the primary prevention of fractures or falls.10

As for children and adolescents, the panel again recommended against routine screening of 25(OH)D levels. They recognized that clinical trial data have not yielded evidence to support routine screening and above-DRI doses of supplementation. An example of the lack of evidence in adults is the randomized-controlled VITamin D and OmegA-3 TriaL (VITAL) in 25 871 generally healthy women and men in whom supplementation with 2000 IU cholecalciferol/day for 5.3 yr did not benefit on a number of health outcomes, including cancer, cardiovascular disease, bone density, and body composition (in sub-cohorts), and incident fractures in the overall cohort.8,11,12

Special attention was given to pregnancy and adults with prediabetes. During pregnancy (ie, generally healthy pregnant individuals), the panel recommended empiric vitamin D supplementation given its known benefits (eg, to lower risk of preterm birth, preeclampsia, small-for-gestational-age birth, etc.).8,13 While an exact dose cannot be concluded from current evidence in the literature, supplementation doses have ranged from 600-5000 IU (15-125 μg) daily. This is another group for whom routine 25(OH)D testing was not recommended. For adults with pre-diabetes, empiric vitamin D supplementation was recommended in addition to lifestyle modification to reduce disease progression and its known health complications. For these two and other patient populations, the 2024 CPG did not include information on the vitamin D doses associated with intoxication, which would be helpful for clinicians.

In contrast to the 2011 CPG, this panel considered vitamin D screening and supplementation in the context of race, skin tone (or complexion), and in adults with obesity (Table 1). Consideration of an individual’s complexion is timely given that there is an appropriate move away from using race as a biological construct and its use as a criterion to assess risk of disease in clinical guidelines. A secondary analysis did not suggest vitamin D’s benefit in those who self-identify as Black, and the panel acknowledged that race may be a proxy for darker skin tone (i.e., with excess melanin). The panel suggested against routine screening of 25(OH) D levels in generally healthy adults with dark complexion, which will also be relevant to such screening in a pediatric population. The panel also noted vitamin D deficiency to be more common in disadvantaged populations, and consideration of socioeconomic status will be an important consideration in the design of future trials. In adults with obesity, specific 25(OH)D thresholds that are associated with clear benefits have not been established in clinical trials. Therefore, routine screening is no longer recommended in the 2024 CPG.

The Endocrine Society’s 2024 CPG on Vitamin D is comprehensive and well-written and is designed to assist endocrinologists and other clinicians regarding measures of vitamin D in the primary prevention setting. A guideline provides recommendations but does not represent the standard of care and, unlike a policy, is not mandated. In our view, the audience for whom the 2024 CPG is written is important to note and, in this case, are the clinicians who care for a generally healthy population of children, adolescents, adults, elders, or pregnant individuals (Table 1). There also needs to be careful consideration given to guide those who care for populations who are at risk for vitamin D deficiency itself (eg, patients with celiac sprue, malabsorption, following bariatric surgery, among others) as was the focus of the 2011 CPG. In addition, for clinicians, it is important to consider secondary prevention for individuals for whom repletion of vitamin D can be helpful in the modulation of a disease, and/or associated with the potential prevention of long-term adverse outcomes (eg, in patients with osteoporosis on therapies associated with hypocalcemia). Large RCTs show that supplementation with the doses of vitamin D3 summarized herein is safe and not generally associated with adverse outcomes such as hypercalcemia and kidney stones. The current CPG needs to be considered carefully by age group, as the take-home message could be misconstrued as suggesting that empiric testing and/or supplementation is rarely needed for any patient. Importantly, the generally healthy population is the focus of the 2024 CPG guideline. An offshoot of the 2011 Endocrine Society’s and other CPGs was that overzealous 25(OH)D testing was occurring, before the cost-effectiveness of such screening had been established. Moving forward, this testing will need to occur more judiciously with a focus on how the measurement may potentially change management and the care of a given patient. Additional and large clinical trials of healthy individuals stratified by age, and also those with obesity and pre-diabetes, will be needed to allow us to understand whether vitamin D lowers the risk of specific outcomes or diseases.14 Additional guidance regarding the appropriate supplementation and treatment cholecalciferol and ergocalciferol doses will also be helpful to clinicians who currently must make an educated guess regarding dosing and then may feel compelled to order a follow-up 25(OH)D measurement to confirm both safety and efficacy. Natural history studies should also be carried out that are of a duration that allows for multiple health outcomes to be examined and vitamin D’s effects on each of them. Until then, speculation continues regarding vitamin D’s purported roles and effects.

Contributor Information

Catherine M Gordon, Section on Adolescent Bone and Body Composition, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, United States.

Meryl S LeBoff, Endocrinology, Diabetes and Hypertension Division, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, United States.

Author contributions

Catherine M. Gordon (Conceptualization, Writing—original draft, Writing—review & editing) and Meryl S. LeBoff (Conceptualization, Writing—original draft, Writing—review & editing)

Funding

M.S.L.: Supported by grants (R01 AR060574, R01 AR070854, and R01 AR059775, to Dr. LeBoff) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The VITAL parent trial is supported by grants (U01 CA138962, R01 CA138962, and R01 AT011729, to Drs. Manson and Buring) from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Office of Dietary Supplements, the National Institute of Neurological Disorders and Stroke, and the National Center for Complementary and Integrative Health.

Conflicts of interest

None declared.

References

  • 1. Ma  NS, Gordon  CM. The truth about vitamin D and adolescent skeletal health. Adolesc Med State Art Rev. 2012;23(3):457–470. [PubMed] [Google Scholar]
  • 2. Holick  MF, Binkley  NC, Bischoff-Ferrari  HA, et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930. 10.1210/jc.2011-0385 [DOI] [PubMed] [Google Scholar]
  • 3.Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Washington (DC): National Academies Press (US); 2011. [PubMed] [Google Scholar]
  • 4. Misra  M, Dl  P, Petryk  A, Collett-Solberg  PF, Kappy  M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122(2):398–417. 10.1542/peds.2007-1894 [DOI] [PubMed] [Google Scholar]
  • 5. Demay  MB, Pittas  AG, Bikle  DD, et al.  Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907–1947. 10.1210/clinem/dgae290 [DOI] [PubMed] [Google Scholar]
  • 6. Munns  CF, Shaw  N, Kiely  M, et al.  Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab. 2016;101(2):394–415. 10.1210/jc.2015-2175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Gou  X, Pan  L, Tang  F, Gao  H, Xiao  D. The association between vitamin D status and tuberculosis in children: a meta-analysis. Medicine. 2018;97(35):e12179. 10.1097/md.0000000000012179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Chou  SH, Murata  EM, Yu  C, et al.  Effects of vitamin D3 supplementation on body composition in the VITamin D and OmegA-3 TriaL (VITAL). J Clin Endocrinol Metab. 2021;106(5):1377–1388. 10.1210/clinem/dgaa981 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Pittas  AG, Dawson-Hughes  B, Sheehan  P, et al.  Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520–530. 10.1056/NEJMoa1900906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. U.S. Preventative Services Task Force . Vitamin D, calcium, or combined supplementation for the primary prevention of falls and fractures in community-dwelling adults: preventive medication (In Progress - draft recommendations). https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/vitamin-d-calcium-combined-supplementation-primary-prevention-falls-fractures-communitydwelling-adults#bootstrap-panel--10
  • 11. Manson  JE, Cook  NR, Lee  I-M, et al.  Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. 10.1056/NEJMoa1809944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. LeBoff  MS, Chou  SH, Ratliff  KA, et al.  Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med. 2022;387(4):299–309. 10.1056/NEJMoa2202106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Tous  M, Villalobos  M, Iglesias  L, Fernández-Barrés  S, Arija  V. Vitamin D status during pregnancy and offspring outcomes: a systematic review and meta-analysis of observational studies. Eur J Clin Nutr. 2020;74(1):36–53. 10.1038/s41430-018-0373-x [DOI] [PubMed] [Google Scholar]
  • 14. Tobias  DK, Manson  JE. The obesity paradox in type 2 diabetes and mortality. Am J Lifestyle Med. 2018;12(3):244–251. 10.1177/1559827616650415 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Bone and Mineral Research are provided here courtesy of Oxford University Press

RESOURCES